NCT05958199 2025-06-27A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7NextPoint Therapeutics, Inc.Phase 1 Suspended131 enrolled
NCT03779100 2019-01-28Lenvatinib Plus PD-1 Antibody for Unresectable ICCSun Yat-sen UniversityPhase 2 Suspended25 enrolled